AU778208C - GRF-containing lyophilized pharmaceutical compositions - Google Patents
GRF-containing lyophilized pharmaceutical compositionsInfo
- Publication number
- AU778208C AU778208C AU62663/00A AU6266300A AU778208C AU 778208 C AU778208 C AU 778208C AU 62663/00 A AU62663/00 A AU 62663/00A AU 6266300 A AU6266300 A AU 6266300A AU 778208 C AU778208 C AU 778208C
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- grf
- solution
- composition according
- saccharose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 claims description 24
- 229930006000 Sucrose Natural products 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 13
- 235000013681 dietary sucrose Nutrition 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 229960004793 sucrose Drugs 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000008247 solid mixture Substances 0.000 claims description 4
- 239000006172 buffering agent Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000011872 intimate mixture Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000009826 distribution Methods 0.000 claims 1
- 239000003488 releasing hormone Substances 0.000 claims 1
- 102100022831 Somatoliberin Human genes 0.000 description 16
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 15
- 101710142969 Somatoliberin Proteins 0.000 description 15
- 238000009472 formulation Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-methyl-PhOH Natural products CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 description 2
- 229960002758 sermorelin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010053803 Sermorelin Proteins 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000011188 deamidation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000003717 m-cresyl group Chemical group [H]C1=C([H])C(O*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- BVLCEKWPOSAKSZ-YQMCHIOTSA-N sermorelin acetate Chemical compound CC(O)=O.C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 BVLCEKWPOSAKSZ-YQMCHIOTSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JAHCMOSSKRAPEL-IBFVROBCSA-N somatorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 JAHCMOSSKRAPEL-IBFVROBCSA-N 0.000 description 1
- 229960002090 somatorelin Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005200879A AU2005200879B2 (en) | 1999-06-30 | 2005-02-25 | GRF-containing lyophilized pharmaceutical compositions |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99112421A EP1064934A1 (fr) | 1999-06-30 | 1999-06-30 | Compositions lyophilisées contenant du GRF |
| EP99112421 | 1999-06-30 | ||
| PCT/EP2000/006061 WO2001001965A1 (fr) | 1999-06-30 | 2000-06-29 | Compositions pharmaceutiques lyophilisees a base de facteur de regulation de la croissance |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005200879A Division AU2005200879B2 (en) | 1999-06-30 | 2005-02-25 | GRF-containing lyophilized pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU6266300A AU6266300A (en) | 2001-01-22 |
| AU778208B2 AU778208B2 (en) | 2004-11-25 |
| AU778208C true AU778208C (en) | 2006-03-09 |
Family
ID=8238452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU62663/00A Ceased AU778208C (en) | 1999-06-30 | 2000-06-29 | GRF-containing lyophilized pharmaceutical compositions |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20060160739A1 (fr) |
| EP (2) | EP1064934A1 (fr) |
| JP (1) | JP4880845B2 (fr) |
| AR (1) | AR024613A1 (fr) |
| AT (1) | ATE249207T1 (fr) |
| AU (1) | AU778208C (fr) |
| CA (1) | CA2374933C (fr) |
| DE (1) | DE60005188T2 (fr) |
| DK (1) | DK1189600T3 (fr) |
| ES (1) | ES2204661T3 (fr) |
| IL (2) | IL147413A0 (fr) |
| PT (1) | PT1189600E (fr) |
| SI (1) | SI1189600T1 (fr) |
| WO (1) | WO2001001965A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1301200A2 (fr) * | 2000-05-19 | 2003-04-16 | Bionebraska, Inc. | Preparations pharmaceutiques peptidiques |
| JP2006504694A (ja) * | 2002-09-18 | 2006-02-09 | サントル・オスピタリエ・ドゥ・リュニヴェルシテ・ドゥ・モントリオール・（シー・エイチ・ユー・エム） | Ｇｈｒｈ類似体 |
| EP2142207A4 (fr) * | 2007-04-04 | 2013-01-16 | Theratechnologies Inc | Formulations pharmaceutiques de molécules ghrh |
| TWI441915B (zh) * | 2007-09-07 | 2014-06-21 | Nisshin Oillio Group Ltd | １，３－二飽和－２－不飽和三酸甘油酯的區分方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5822445B2 (ja) * | 1982-07-08 | 1983-05-09 | 株式会社 ミドリ十字 | 安定な固体の人血漿コリンエステラ−ゼ製剤の製法 |
| US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
| DE3579911D1 (de) * | 1984-12-24 | 1990-10-31 | Sumitomo Pharma | Stabiles grf-praeparat. |
| JPH0725696B2 (ja) * | 1986-05-29 | 1995-03-22 | 株式会社ミドリ十字 | プラスミノ−ゲンの安定化方法 |
| US5017557A (en) * | 1987-07-24 | 1991-05-21 | Industria Farmaceutica Serono S.P.A. | Treatment of infertility with somatotrophin releasing factor |
| US4880777A (en) * | 1987-09-01 | 1989-11-14 | Eastman Kodak Company | Synthetic peptides having growth hormone releasing activity |
| AU634529B2 (en) * | 1989-03-17 | 1993-02-25 | Pitman-Moore, Inc. | Controlled release delivery device for macromolecular proteins |
| JPH0383931A (ja) | 1989-08-29 | 1991-04-09 | Sumitomo Pharmaceut Co Ltd | 低刺激性ｇｒｆ経鼻投与製剤 |
| US5132401A (en) * | 1989-09-19 | 1992-07-21 | George Washington University, Office Of Sponsored Research | MB-35 a peptide enhancing the production of growth hormone and prolactin from the anterior pituitary |
| JPH04264020A (ja) * | 1991-02-18 | 1992-09-18 | Yamanouchi Pharmaceut Co Ltd | 安定な凍結乾燥製剤 |
| EP0580778B1 (fr) * | 1991-04-19 | 1999-08-11 | LDS Technologies, Inc. | Formulations de microemulsions a inversion de phase |
| JP3140797B2 (ja) * | 1991-04-26 | 2001-03-05 | 生化学工業株式会社 | 安定化コンドロイチナーゼａｂｃ、その保存方法及び治療剤 |
| YU87892A (sh) * | 1991-10-01 | 1995-12-04 | Eli Lilly And Company Lilly Corporate Center | Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu |
| SI9300468A (en) * | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| JP3083931B2 (ja) | 1993-02-24 | 2000-09-04 | 大阪瓦斯株式会社 | 吸収式冷凍機の故障診断システム |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| WO1995035116A1 (fr) | 1994-06-17 | 1995-12-28 | Applied Research Systems | Compositions pharmaceutiques renfermant l'hch |
| US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| BR9609743A (pt) * | 1995-07-27 | 1999-03-02 | Genentech Inc | Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0880969A1 (fr) * | 1997-05-28 | 1998-12-02 | Applied Research Systems ARS Holdings N.V. | Compositions pharmaceutiques de peptides de faible solubilité dans un milieu physioloqique |
| US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| US6759393B1 (en) * | 1999-04-12 | 2004-07-06 | Pfizer Inc. | Growth hormone and growth hormone releasing hormone compositions |
| JP4330280B2 (ja) | 2001-01-12 | 2009-09-16 | 株式会社小松製作所 | エンジンの燃料噴射制御方法及びその制御装置 |
-
1999
- 1999-06-30 EP EP99112421A patent/EP1064934A1/fr not_active Withdrawn
-
2000
- 2000-06-29 WO PCT/EP2000/006061 patent/WO2001001965A1/fr active IP Right Grant
- 2000-06-29 EP EP00949226A patent/EP1189600B1/fr not_active Expired - Lifetime
- 2000-06-29 DK DK00949226T patent/DK1189600T3/da active
- 2000-06-29 IL IL14741300A patent/IL147413A0/xx active IP Right Grant
- 2000-06-29 ES ES00949226T patent/ES2204661T3/es not_active Expired - Lifetime
- 2000-06-29 AU AU62663/00A patent/AU778208C/en not_active Ceased
- 2000-06-29 AT AT00949226T patent/ATE249207T1/de active
- 2000-06-29 PT PT00949226T patent/PT1189600E/pt unknown
- 2000-06-29 AR ARP000103297A patent/AR024613A1/es unknown
- 2000-06-29 CA CA2374933A patent/CA2374933C/fr not_active Expired - Lifetime
- 2000-06-29 DE DE60005188T patent/DE60005188T2/de not_active Expired - Lifetime
- 2000-06-29 SI SI200030199T patent/SI1189600T1/xx unknown
- 2000-06-29 JP JP2001507460A patent/JP4880845B2/ja not_active Expired - Fee Related
-
2001
- 2001-12-31 IL IL147413A patent/IL147413A/en unknown
-
2006
- 2006-03-01 US US11/364,079 patent/US20060160739A1/en not_active Abandoned
-
2007
- 2007-05-03 US US11/744,073 patent/US8431534B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2374933C (fr) | 2010-10-12 |
| IL147413A0 (en) | 2002-08-14 |
| DE60005188T2 (de) | 2004-04-01 |
| DE60005188D1 (de) | 2003-10-16 |
| SI1189600T1 (en) | 2003-12-31 |
| AU778208B2 (en) | 2004-11-25 |
| WO2001001965A1 (fr) | 2001-01-11 |
| JP4880845B2 (ja) | 2012-02-22 |
| US20060160739A1 (en) | 2006-07-20 |
| ATE249207T1 (de) | 2003-09-15 |
| AU6266300A (en) | 2001-01-22 |
| AR024613A1 (es) | 2002-10-16 |
| CA2374933A1 (fr) | 2001-01-11 |
| JP2003503443A (ja) | 2003-01-28 |
| DK1189600T3 (da) | 2004-01-26 |
| US20070203069A1 (en) | 2007-08-30 |
| US8431534B2 (en) | 2013-04-30 |
| IL147413A (en) | 2006-10-31 |
| ES2204661T3 (es) | 2004-05-01 |
| PT1189600E (pt) | 2003-12-31 |
| EP1064934A1 (fr) | 2001-01-03 |
| EP1189600B1 (fr) | 2003-09-10 |
| EP1189600A1 (fr) | 2002-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2405994T5 (es) | Soluciones estabilizadas de teriparatide | |
| US7056886B2 (en) | GLP-2 formulations | |
| US7144861B2 (en) | Stabilized teriparatide solutions | |
| JP4353544B2 (ja) | アミリン作動薬ペプチド用製剤 | |
| JP2005537232A (ja) | アミリンアゴニストペプチドの製剤 | |
| JP4255515B2 (ja) | 安定化された成長ホルモン処方物およびその製造方法 | |
| CA2528988C (fr) | Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique | |
| US8431534B2 (en) | GRF-containing lyophilized pharmaceutical compositions | |
| IL133176A (en) | Pharmaceutical preparations containing peptides in a low solubility vessel in a physiological medium | |
| EP3423042B1 (fr) | Formulation pharmaceutique lyophilisée et son utilisation | |
| JP3555961B2 (ja) | 安定なペプチド医薬組成物 | |
| AU2005200879B2 (en) | GRF-containing lyophilized pharmaceutical compositions | |
| JPS63303931A (ja) | 経鼻投与用成長ホルモン放出活性物質製剤 | |
| JPH05345729A (ja) | カルシトニン類の安定化組成物および安定化法 | |
| KR20230035600A (ko) | Ghrh 유사체의 저-용량 약제학적 조성물 및 이들의 용도 | |
| JP2009149684A (ja) | アミリン作動薬ペプチド用製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |